Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy [0.03%]
mavacamten：治疗肥厚型心肌病的新疗法综述
Ayesha Abdul Qadir Memon,Areeba Shamim,Sanoober Mirza et al.
Ayesha Abdul Qadir Memon et al.
Hypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) ...
Redox-signalling and Redox Biomarkers in Cardiovascular Health and Disease [0.03%]
心血管健康和疾病中的红氧信号及红氧生物标志物
Yasmin Sultana,Damanpreet Kaur Lang,Thomson Santosh Alex et al.
Yasmin Sultana et al.
Overproduction of reactive nitrogen and oxygen species (RNS and ROS) has been linked to the pathogenesis of diabetes, hypertension, hyperlipidemia, stroke, angina, and other cardiovascular diseases. These species are produced in part by the...
Effect of Syzygium cumini on Oxidative Stress Induced Cardiac Cellular Anomalies [0.03%]
Syzygium cumini 对氧化应激诱导的心脏细胞异常的影响
Renu Bhadana,Vibha Rani
Renu Bhadana
Introduction: Doxorubicin (Dox), an antineoplastic agent is used as a primary anticancerous drug against various types of cancers. However, its associated toxicity to the cardiovascular system is major. Literature has rec...
A Three-year Retrospective Study Looking at Preventing Hospital Acquired Thrombosis [0.03%]
防止医院获得性血栓的三年回顾性研究
Vipin Kammath,Anuj Gupta,Alexander Bald et al.
Vipin Kammath et al.
Background: Hospital-acquired venous thromboembolism (HA-VTE) is defined as cases of venous thromboembolism (VTE) that occur in a hospital and within ninety days of a hospital admission. Deep vein thromboses (DVTs) most c...
Basheer Abdullah Marzoog
Basheer Abdullah Marzoog
Background: Post-myocardial infarction (MI) changes have been frequently reported in the literature and are associated with determining the prognosis. Aim...
Sushweta Mahalanobish,Sumit Ghosh,Parames C Sil
Sushweta Mahalanobish
Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disorder, in which genetic and environmental factors are involved in disease onset. Although, by definition, the disease is considered idiopathic...
Antihypertensive and ACE-2 Inhibitory Effects of Daphne gnidium in Rats [0.03%]
Daphne gnidium对大鼠的抗高血压及ACE-2抑制作用
Ismail Bouadid,Adil Qabouche,Mohamed Eddouks
Ismail Bouadid
Aims: The antihypertensive activity of Daphne gnidium was tested. Background: Daphne gnidium (Thymelaeaceae) is used against hypertensi...
Can Rosuvastatin Reduce the Risk of Thrombosis in Patients with Hypercholesterolemia with its Effect on Coagulation Factors and Homocysteine Levels? [0.03%]
瑞舒伐他汀能否通过其对凝血因子和同型半胱氨酸水平的影响来降低高胆固醇患者发生血栓的风险？
Mostafa Behnam,Mohammad Reza Deyhim,Parichehreh Yaghmaei
Mostafa Behnam
Background and objective: Hypercholesterolemia is one of the main risk factors for vascular thrombosis in individuals. Therefore, the use of statins is very effective in reducing cholesterol and can reduce the risk of thr...
The Role of Gut Microbiota and Associated Compounds in Cardiovascular Health and its Therapeutic Implications [0.03%]
肠道菌群及其相关化合物在心血管健康中的作用及其治疗意义
Lu Liu,Guneet Inderjeet Kaur,Avinash Kumar et al.
Lu Liu et al.
It is possible that gut bacteria may have a beneficial effect on cardiovascular health in humans. It may play a major role in the progression of a variety of cardiovascular diseases, including Heart Failure (HF), Atherosclerosis, Coronary A...
Efficacy of Dyslipidemia Control by Combination Therapy with Rosuvastatin 10 Mg and Ezetimibe 10 Mg Compared with Rosuvastatin 20 Mg Monotherapy in Patients with Chronic Coronary Syndromes: A Randomized, Single-blind Controlled Trial [0.03%]
以Rosuvastatin 10毫克和Ezetimibe 10毫克联合治疗与单用Rosuvastatin 20毫克对比，对慢性冠状动脉综合征患者血脂异常控制的有效性：一项随机、单盲对照试验
An Viet Tran,Bao Lam Thai Tran,Nghia Minh Bui et al.
An Viet Tran et al.
Background: Studies have shown the combination treatment effectiveness of using rosuvastatin and ezetimibe in patients with chronic coronary artery disease. Our study aim to evaluate the effectiveness of dyslipidemia trea...